Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.87 USD
+0.27 (7.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth A Momentum B VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 31% (77 out of 252)Zacks Sector Rank
Top 13% (2 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 2.63 | 1.37 | 9.99 |
Current Quarter Estimate | -0.40 | 3.00 | 63.00 |
Year Ago Quarter Estimate | -0.39 | -4.79 | 52.25 |
Next Quarter Estimate | -0.32 | 3.82 | 66.00 |
Next Year Estimate | -1.14 | 24.58 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 82.39 | 17.80 | 15.67 |
Next Year | -307.14 | 9.50 | 11.34 |
Last 5 Years | NA | 0.90 | 8.10 |
Next 5 Years | 57.70 | 21.40 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -6.95 |
Price/Book (MRQ) | 0.82 | 2.03 |
Price/Cash Flow (MRFY) | NA | 16.44 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | NA | -163.24% |
Return on Equity (TTM) | -8.28% | -61.40% |
Debt to Equity (MRQ) | NA | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.